Live Breaking News & Updates on Clinical research at dana farber cancer institute

Stay updated with breaking news from Clinical research at dana farber cancer institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Combination Approaches Are on the Horizon in Later-Line HER2+ Breast Cancer Management

Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management. ....

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Adrienneg-waks , Harvard-medical-school , Clinical-research-at-dana-farber-cancer-institute , Clinical-research , Trastuzumab-emtansine-plus-tucatinib , Monarcher-trial , Nct02675231

HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents

Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape. ....

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Adrienneg-waks , Clinical-research-at-dana-farber-cancer-institute , Harvard-medical-school , Clinical-research , Patients-with-her2-positive-breast-cancer , D , Adjuvant-trastuzumab-emtansine